

Variant: *NM_000546.6(TP53):c.946C>A (p.Pro316Thr)*

Version: 2.0

CA001212 [↗](#)

230382 (ClinVar) [↗](#)

Gene: TP53 ([HGNC:7157](#))

Condition: Li-Fraumeni syndrome ([MONDO:0018875](#))

Inheritance Mode: Autosomal dominant inheritance

UUID: f2e706ef-eea4-48c8-917b-970c7c07543c

Approved on: 2025-03-04

Published on: 2025-06-23

HGVS expressions

NM_000546.6:c.946C>A

NM_000546.6(TP53):c.946C>A (p.Pro316Thr)

NC_000017.11:g.7673582G>T

CM000679.2:g.7673582G>T

NC_000017.10:g.7576900G>T

CM000679.1:g.7576900G>T

NC_000017.9:g.7517625G>T

NG_017013.2:g.18969C>A

ENST00000503591.2:c.946C>A

ENST00000508793.6:c.946C>A

ENST00000509690.6:c.550C>A

ENST00000514944.6:c.667C>A

ENST00000604348.6:c.925C>A

ENST00000269305.9:c.946C>A

ENST00000269305.8:c.946C>A

ENST00000359597.8:c.946C>A

ENST00000413465.6:c.782+599C>A

ENST00000420246.6:c.946C>A

ENST00000445888.6:c.946C>A

ENST00000455263.6:c.946C>A

ENST00000504290.5:c.550C>A

ENST00000504937.5:c.550C>A

ENST00000509690.5:c.550C>A

ENST00000510385.5:c.550C>A

ENST00000576024.1:c.6C>A

ENST00000610292.4:c.829C>A

ENST00000610538.4:c.829C>A

ENST00000610623.4:c.469C>A

ENST00000615910.4:c.913C>A

ENST00000617185.4:c.946C>A

ENST00000618944.4:c.469C>A

ENST00000619186.4:c.469C>A

ENST00000619485.4:c.829C>A

ENST00000620739.4:c.829C>A

ENST00000622645.4:c.829C>A

ENST00000635293.1:c.829C>A

NM_000546.5:c.946C>A

NM_001126112.2:c.946C>A
NM_001126113.2:c.946C>A
NM_001126114.2:c.946C>A
NM_001126115.1:c.550C>A
NM_001126116.1:c.550C>A
NM_001126117.1:c.550C>A
NM_001126118.1:c.829C>A
NM_001276695.1:c.829C>A
NM_001276696.1:c.829C>A
NM_001276697.1:c.469C>A
NM_001276698.1:c.469C>A
NM_001276699.1:c.469C>A
NM_001276760.1:c.829C>A
NM_001276761.1:c.829C>A
NM_001276695.2:c.829C>A
NM_001276696.2:c.829C>A
NM_001276697.2:c.469C>A
NM_001276698.2:c.469C>A
NM_001276699.2:c.469C>A
NM_001276760.2:c.829C>A
NM_001276761.2:c.829C>A
NM_001126112.3:c.946C>A
NM_001126113.3:c.946C>A
NM_001126114.3:c.946C>A
NM_001126115.2:c.550C>A
NM_001126116.2:c.550C>A
NM_001126117.2:c.550C>A
NM_001126118.2:c.829C>A
NM_001276695.3:c.829C>A
NM_001276696.3:c.829C>A
NM_001276697.3:c.469C>A
NM_001276698.3:c.469C>A
NM_001276699.3:c.469C>A
NM_001276760.3:c.829C>A
NM_001276761.3:c.829C>A

Likely Benign

Met criteria codes 3

- BS2_Supporting
- BP4
- PM2_Supporting

Not Met criteria codes 13

- PM1
- PM5
- PM6
- PS1
- PS2
- PS3
- PS4
- PP1
- PP3
- BA1
- BS1
- BS4
- BS3

Evidence Links 2

Expert Panel

TP53 VCEP

Criteria Specification Information

[Criteria Specification:](#) ClinGen TP53 Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for TP53 Version 2.3.0

[Criteria Specification Approval History](#)

[Criteria Specifications for this VCEP](#)

Evidence submitted by expert panel

TP53 VCEP

The NM_000546.6:c.946C>A variant in TP53 is a missense variant predicted to cause substitution of proline by threonine at amino acid 316 (p.Pro316Thr). Although this variant has been observed in germline cases, to our knowledge, this variant has not been reported in individuals meeting classical LFS or Chompret criteria (PS4 not met; Internal lab contributors). This variant has been observed in 2-3 heterozygous unrelated females from the same data source with no personal history of cancer prior to age 60 years and no personal history of sarcoma at any age (BS2_Supporting; Internal lab contributor). This variant has an allele frequency of 0.000003098 (5/1614040 alleles) across gnomAD v4.1.0 which is lower than the ClinGen TP53 VCEP threshold (<0.00003) for PM2_Supporting and has a subpopulation allele frequency of <0.00004 in all non-bottleneck populations with 2 or more alleles present (PM2_Supporting). In vitro assays performed in yeast and/or human cell lines showed conflicting results with respect to transactivation, growth suppression activity, and/or tetramer formation (PS3/BS3 not met; PMIDs: 12826609, 16007150, 29979965, 30224644). Computational predictor scores (BayesDel = -0.0226052; Align GVGD Class C0) are below the recommended thresholds (BayesDel ≤ -0.008 and an Align GVGD Class ≤ 55), evidence that does not predict a damaging effect on TP53 via protein change. SpliceAI predicts that the variant has no impact on splicing. (BP4_Moderate). In summary this variant meets the criteria to be classified as Likely Benign for Li Fraumeni syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen TP53 VCEP: BS2_Supporting, PM2_Supporting, BP4_Moderate. (Bayesian Points: -2; VCEP specifications version 2.3)

Met criteria codes

BS2_Supporting			This variant has been observed in 2-3 heterozygous unrelated females from the same data source with no personal history of cancer prior to age 60 years and no personal history of sarcoma at any age (BS2_Supporting; Internal lab contributor).
BP4			BP4_MODERATE Computational predictor scores (BayesDel = -0.0226052; Align GVGD Class C0) are below the recommended thresholds (BayesDel ≤ -0.008 and an Align GVGD Class ≤ 55), evidence that does not predict a damaging effect on TP53 via protein change. SpliceAI predicts that the variant has no impact on splicing. (BP4_Moderate).
PM2_Supporting			This variant has an allele frequency of 0.000003098 (5/1614040 alleles) across gnomAD v4.1.0 which is lower than the ClinGen TP53 VCEP threshold (<0.00003) for PM2_Supporting and has a subpopulation allele frequency of <0.00004 in all non-bottleneck populations with 2 or more alleles present (PM2_Supporting).

Not Met criteria codes

PM1			This variant does not reside within a region of TP53 that is defined as a mutational hotspot by the ClinGen TP53 VCEP (PM1 not met).
PM5			2 different missense variants (p.Pro316Leu, p.Pro316Ser) in the same codon have been reported (ClinVar Variation IDs:528273, 823268). However, these variants have a higher Grantham score than p.Pro316Thr and do not meet criteria for PM5 code application (PM5 not met).
PM6			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS1			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline

PS2			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS3			In vitro assays performed in yeast and/or human cell lines showed conflicting results with respect to transactivation, growth suppression activity, and/or tetramer formation (PS3/BS3 not met; PMIDs: 12826609, 30224644) No LOF, 0.5457 PubMed:30224644  Non-functional 12.9% PubMed:12826609 
PS4			Although this variant has been observed in germline cases, to our knowledge, this variant has not been reported in individuals meeting classical LFS or Chompret criteria (PS4 not met; Internal lab contributors).
PP1			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PP3			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BA1			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS1			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS4			No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS3			In vitro assays performed in yeast and/or human cell lines showed conflicting results with respect to transactivation, growth suppression activity, and/or tetramer formation (PS3/BS3 not met; PMIDs: 12826609, 16007150, 29979965, 30224644) No LOF, 0.5457 PubMed:30224644  Non-functional 12.9% PubMed:12826609 

Curation History 

Showing 1 to 2 of 2 rows

See Report	Preferred Variant Title	Classification ⓘ	Condition	Published Date	Version ⓘ	Criteria Specification	Gene
View	NM_000546.6(TP53):c.946C>A (p.Pro3...	Likely Benign	Li-Fraumeni Syndrome ↗	2025-06-23	2.0	ClinGen TP53 Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for TP53 Version 2.3.0 ↗	TP53 ↗
View	NM_000546.5(TP53):c.946C>A (p.Pro3...	Uncertain Significance	Li-Fraumeni Syndrome 1 ↗	2021-09-24	1.0	-	TP53 ↗

Showing 1 to 2 of 2 rows

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.